Related Experiment Video
Updated: Jun 23, 2026
07:41
Induction and Phenotyping of Acute Right Heart Failure in a Large Animal Model of Chronic Thromboembolic Pulmonary Hypertension
Published on: March 17, 2022
Therapy for acute heart failure syndromes
Sarah M Donlan1, Erin Quattromani, Peter S Pang
1Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, 259 East Erie Street, Suite 100, Chicago, IL 60611, USA.
Current Cardiology Reports
|April 22, 2009
Summary
Pharmacologic management for acute heart failure syndromes remains largely unchanged. Traditional therapies like nitrates and diuretics are mainstays, with inotropes used for shock or low-output states, informed by recent data.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Acute heart failure syndromes (AHFS) management has seen limited evolution over 15 years.
- Nitrates and loop diuretics are the primary treatments for AHFS.
- Inotropes are typically reserved for patients in shock or with advanced low-output states.
Purpose of the Study:
- To review current pharmacologic therapies for AHFS.
- To provide insights from recent clinical trials and registry data on AHFS management.
- To highlight the enduring role of traditional therapies in AHFS.
Main Methods:
- Review of existing literature on AHFS pharmacologic management.
- Analysis of recent clinical trial outcomes related to AHFS therapies.
- Examination of registry data for insights into real-world AHFS treatment patterns.
Main Results:
- Traditional therapies (nitrates, loop diuretics) continue to be the cornerstone of AHFS treatment.
- The indications for inotropic agents in AHFS remain focused on severe presentations like shock.
- Recent data reinforce the established therapeutic approaches rather than introducing novel mainstays.
Conclusions:
- The pharmacologic approach to AHFS is largely consistent with historical practices.
- Nitrates and diuretics remain essential for managing acute heart failure.
- Evidence from recent studies supports the continued use of established therapies in AHFS.
Related Concept Videos
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...